Abstract:Cancer cells exhibit a distinct metabolic profile that features an upregulation of less efficient glycolysis accompanied by lactate production for energy generation, in contract to the characteristic metabolism of normal cells. Consequently, cancer research has focused on the enzymes that participate in these cancer metabolic pathways. Among them, hexokinase 2 (HK2) has an important position as the initial enzyme in the glycolytic pathway. Increased expression levels of HK2 have been correlated with an increased risk of poor patient outcomes and advanced tumor stages in a number of malignant tumors, such as gastric carcinoma. The present study aimed to investigate the specific role of HK2 in patients diagnosed with esophageal adenocarcinoma. A total of 643 patients with esophageal adenocarcinoma were included. Immunohistochemical staining and HK2 mRNA in situ probes were used to investigate the association of HK2 expression levels with clinical and molecular tumor characteristics. Patients who exhibited high HK2 expression levels demonstrated significantly reduced overall survival (OS) times compared with patients who exhibited low HK2 expression levels (29.6 vs. 39.9 months, respectively; P=0.027). Furthermore, high HK2 expression levels were demonstrated to be an independent risk factor for reduced patient survival (hazard ratio, 1.65; 95% CI, 1.09-2.50; P=0.018). Significantly reduced patient survival was also demonstrated in the subgroups of male patients, patients with primarily resected tumors, patients with HER2-negative tumors and patients with tumors exhibiting Y chromosome loss. Elevated expression of HK2 was identified as a risk factor for unfavorable patient survival in esophageal adenocarcinoma. This revelation suggests the potential for future diagnostic and therapeutic avenues tailored to this specific patient subset. Identifying patients with high HK2 expression may pinpoint a higher-risk cohort, paving the way for comprehensive prospective studies that could advocate for intensified monitoring and more aggressive therapeutic regimens. Furthermore, the targeted inhibition of HK2 could hold promise as a strategy to potentially enhance patient outcomes.

Research progress of hexokinase 2 in inflammatory-related diseases and its inhibitors

HK2 in Microglia and Macrophages Contribute to the Development of Neuropathic Pain.

Hexokinase 2 expression in apical enterocytes correlates with inflammation severity in patients with inflammatory bowel disease

Targeted Inhibition of HK-II Reversed the Warburg Effect to Improve the Radiosensitivity of Laryngeal Carcinoma.

The Promoting Role of HK II in Tumor Development and the Research Progress of Its Inhibitors

HK2: Gatekeeping Microglial Activity by Tuning Glucose Metabolism and Mitochondrial Functions

Hexokinase 2-Mediated Glycolysis Supports Inflammatory Responses to Porphyromonas Gingivalis in Gingival Fibroblasts.

Dual roles of hexokinase 2 in shaping microglial function by gating glycolytic flux and mitochondrial activity

Hexokinase 2 as a novel selective metabolic target for rheumatoid arthritis

Development of Inflammatory Immune Response-Related Drugs Based on G Protein-Coupled Receptor Kinase 2

HK2: a potential regulator of osteoarthritis via glycolytic and non-glycolytic pathways

Hexokinase 2 in Cancer: A Prima Donna Playing Multiple Characters

The role of hexokinases in epigenetic regulation: altered hexokinase expression and chromatin stability in yeast

Degradation of Hexokinase 2 Blocks Glycolysis and Induces GSDME-Dependent Pyroptosis to Amplify Immunogenic Cell Death for Breast Cancer Therapy

Targeted degradation of hexokinase 2 for anti‐inflammatory treatment in acute lung injury

A pan-cancer analysis of the role of hexokinase II (HK2) in human tumors

Hexokinase 2 as an independent risk factor for worse patient survival in esophageal adenocarcinoma and as a potential therapeutic target protein: A retrospective, single‑center cohort study

Hexokinases in Cancer and Other Pathologies

PKM2: A Potential Regulator of Rheumatoid Arthritis Via Glycolytic and Non-Glycolytic Pathways

Microbial regulation of hexokinase 2 links mitochondrial metabolism and cell death in colitis